EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Phenotype and Prognostic Factors in Geriatric and Non-Geriatric Patients with Transthyretin Cardiomyopathy

Eugenia Volpentesta, Mounira Kharoubi, Cristiano Donadio, Kahina Rebiai, Pascale Fanen, Benoit Funalot, Thierry Gendre, Vincent Audard, Florence Canoui-Poitrine, Emmanuel Itti, Emmanuel Teiger, Violaine Planté-Bordeneuve und 6 weitere

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14793 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Eugenia Volpentesta und 17 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Geriatrics, AP-HP (Assistance Publique-Hôpitaux de Paris), Henri-Mondor/Albert-Chenevier Hospital, Créteil, France. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Phenotype, Cardiomyopathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Transthyretin cardiac amyloidosis (ATTR-CM) may be an underestimated cause of heart failure among geriatric patients and represent a unique phenotype and prognostic profile. Methods and results This retrospective, observational, cohort study characterizes cardiac and extracardiac disorders at diagnosis and assesses prognosis among ATTR-CM patients based on age (geriatric vs. non-geriatric) and amyloidosis subtype (wild type, ATTRwt and hereditary, ATTRv). In total, 943 patients with ATTR-CM were included, of which 306 had ATTRv and 637 had ATTRwt. Among these, 331 (35.1%) were non-geriatric (<75 years), and 612 (64.9%) were geriatric (≥75 years). The population exhibited conduction abnormalities, atrial fibrillation and ischaemic heart disease that progressively deteriorated with age. Among ATTRwt patients, peripheral neuropathy, neurovegetative symptoms, and hearing loss were present across all age groups, but reports of carpal tunnel symptoms or surgery decreased with age. Conversely, among ATTRv patients, reports of extracardiac symptoms increased with age and Val122ILe mutation was highly prevalent among geriatric patients. The 3-year survival was higher among non-geriatric ATTR-CM patients (76%) than geriatric patients (55%) and predictors of 3-year mortality differed. Notably, predictors identified among geriatric patients were alkaline phosphatase (ALP) (HR = 1.004, 95% CI: [0.001–1.100)], troponin T hs (HR = 1.005, 95% CI: [1.001–1.120)] and tricuspid insufficiency (HR = 1.194, 95% CI: [1.02–1.230)]. Whereas, among non-geriatric patients, NT-proBNP (HR = 1.002, 95% CI: [1.02–1.04], global longitudinal strain (HR = 0.95, 95% CI: [0.922–0.989], and glomerular filtration rate (HR = 0.984, 95% CI: [0.968–1.00) were identified. We propose a 3-stage prognostic staging system combining troponin T hs (≥44 ng/L) and ALP levels (≥119 UI/L). In the geriatric population, this model discriminated survival more precisely than the National Amyloidosis Centre staging, particularly for classifying between stage 1 (82%), stage 2 (50%) and stage 3 (32%) for ATTRv and ATTRwt.

Conclusions

These diagnostic and prognostic indicators, along with ATTR subtype, highlight the distinct characteristics of this important, geriatric ATTR-CM patient group. Recognizing these mortality markers can be valuable for geriatricians to improve the prognostic quality management of geriatric patients with ATTR-CM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialPhenotypeCardiomyopathiesHumansMaleFemaleAgedRetrospective StudiesPrognosisAged, 80 and overFollow-Up StudiesMiddle AgedSurvival RateAge FactorsMutation

Stichwörter der Autor:innen

ATTR‐CMGenetic testingGeriatricObservationalPrognostic factors

Autor:innen und Institutionen

  • Departement of Geriatrics, AP-HP (Assistance Publique-Hôpitaux de Paris), Henri-Mondor/Albert-Chenevier Hospital, Créteil, France.
  • Departement of Geriatrics, AP-HP (Assistance Publique-Hôpitaux de Paris), Charles Foix Hospital, Ivry-sur-seine, France.
  • Department of Cardiology, AP-HP (Assistance Publique-Hôpitaux de Paris), DMU Care, Henri Mondor University Hospital, Créteil, France.
  • Cardiac Amyloidosis Referral Centre, Cardiogen Network, AP-HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor University Hospital, Créteil, France.
  • GRC Amyloid Research Institute, AP-HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor University Hospital, Créteil, France.
  • DHU A-TVB, AP-HP (Assistance Publique-Hôpitaux de Paris), Henri Mondor University Hospital, Créteil, France.

ORCID-Profile: Thibaud Damy

Zitieren

APA

Volpentesta, E., Kharoubi, M., Donadio, C., Rebiai, K., Fanen, P., Funalot, B., Gendre, T., Audard, V., Canoui-Poitrine, F., Itti, E., Teiger, E., Planté-Bordeneuve, V., Oghina, S., Tixier, D., Mallet, S., Broussier, A., Damy, T., & Zaroui, A. (2024). Phenotype and Prognostic Factors in Geriatric and Non-Geriatric Patients with Transthyretin Cardiomyopathy. ESC Heart Failure. https://doi.org/10.1002/ehf2.14793

Vancouver

Volpentesta E, Kharoubi M, Donadio C, Rebiai K, Fanen P, Funalot B, et al. Phenotype and Prognostic Factors in Geriatric and Non-Geriatric Patients with Transthyretin Cardiomyopathy. ESC Heart Failure. 2024. doi:10.1002/ehf2.14793

BibTeX
@article{Volpentesta2024,
  author = {Volpentesta, Eugenia and Kharoubi, Mounira and Donadio, Cristiano and Rebiai, Kahina and Fanen, Pascale and Funalot, Benoit and Gendre, Thierry and Audard, Vincent and Canoui-Poitrine, Florence and Itti, Emmanuel and Teiger, Emmanuel and Planté-Bordeneuve, Violaine and Oghina, Silvia and Tixier, Denis and Mallet, Sophie and Broussier, Amaury and Damy, Thibaud and Zaroui, Amira},
  title = {Phenotype and Prognostic Factors in Geriatric and Non-Geriatric Patients with Transthyretin Cardiomyopathy},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14793}
}
Kostenlos starten →